Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Diagnosis and Initial Assessment

• The diagnosis of ME/CFS requires profound fatigue lasting ≥6 months with substantial reduction in pre-illness activities, accompanied by postexertional malaise, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance, as recommended by the American Academy of Family Physicians 1.
• Systematically rule out treatable conditions causing chronic fatigue, including anemia, hypothyroidism, depression, and anxiety disorders, before attributing symptoms solely to ME/CFS, according to the Mayo Clinic Proceedings 1.
• Conduct psychosocial assessment, including psychological trauma history, and obtain complete medical history, as suggested by the Mayo Clinic Proceedings 2, 3.

Non-Pharmacological Management

• Offer structured cognitive-behavioral therapy (CBT) as the primary intervention, which demonstrates the strongest evidence for improving health function, quality of life, and physical functioning in ME/CFS, as recommended by the American College of Physicians 1, 4, 5.
• Promote a consistent pattern of activity, rest, and sleep, starting physical activity at low intensity and gradually increasing based on tolerance, as suggested by the American Academy of Family Physicians 1.
• Consider mindfulness-based interventions, such as mindfulness-based stress reduction and mindfulness-based cognitive therapy, for enhancing quality of life, with moderate effect sizes compared to waitlist or support group controls, according to the American Psychological Association 1, 4.

Physical Activity Interventions

• Introduce physical exercise gradually, as it has shown statistical benefits in improving quality of life and reducing pain, but must be carefully titrated to avoid postexertional malaise, as recommended by the American College of Sports Medicine 4, 3.
• Offer yoga or tai chi, which demonstrate significant improvements in physical functioning, quality of life, pain, fatigue, sleep quality, and mood, with longer duration of treatment showing greater improvement, according to the National Institutes of Health 2, 3, 6, 4.

Pharmacological Management

• Avoid stimulants, corticosteroids, antivirals, or antibiotics for ME/CFS, as they have no demonstrated benefit, as stated by the American Academy of Family Physicians 1, 4, 5.
• Consider serotonin-norepinephrine reuptake inhibitors (SNRIs) or pregabalin for pain management and improved functional status, though evidence is insufficient specifically for ME/CFS fatigue, as suggested by the American Pain Society 1, 4.
• Bupropion may be considered for fatigue management based on favorable results in open-label trials, though evidence is limited, according to the American Academy of Neurology 4.

Management of Dizziness and Headaches

• Address orthostatic intolerance, which is a core diagnostic feature of ME/CFS and commonly manifests as dizziness, by increasing fluid and salt intake, considering compression stockings, and educating patients on positional changes, as recommended by the American Autonomic Society 1, 2, 3.
• Treat headaches according to standard migraine protocols when appropriate, recognizing that headache is a common symptom in chronic multisymptom illness, as suggested by the American Headache Society 2, 3, 6, 7.

Complementary Approaches

• Consider manual acupuncture as part of management, with evidence supporting its effectiveness, as recommended by the National Institutes of Health 8, 4.
• Emotion-focused therapy should be considered as it has shown benefits for patients with chronic multisymptom illness, according to the American Psychological Association 8, 4.

Monitoring and Follow-Up

• Reassess fatigue levels at every visit using the same 0-10 numeric scale to track response, and modify management strategies based on response and changes in clinical status, as recommended by the American Academy of Family Physicians 1.
• Regularly assess fatigue severity, impact, and coping strategies in clinical consultations, and consider referral to mental health professionals, physical therapists, rheumatologists, sleep specialists, and integrative medicine specialists for comprehensive management of ME/CFS, as suggested by the Mayo Clinic Proceedings 4, 2, 3.

Hydrocodone Use in CFS/ME: Strong Recommendation Against

Primary Guideline Recommendation

• The VA/DoD Clinical Practice Guideline for Chronic Multisymptom Illness recommends against the long-term use of opioid medications for managing chronic pain in patients with CMI, which includes ME/CFS, as potential harms and burdens of opioid use outweigh any theoretical benefits in this population 9, 10, 11
• The American College of Physicians and other guideline societies support this recommendation, emphasizing the importance of weighing the risks and benefits of opioid therapy in patients with chronic pain 9, 10, 11

Specific Risks and Concerns in CFS/ME

• The use of hydrocodone in CFS/ME patients poses a substantial risk of addiction and dependency, with a reported abuse rate of 1.2% in general populations, and the chronic nature of ME/CFS creates prolonged exposure risk 12
• Opioids can cause gastrointestinal effects, including constipation and slow gastric emptying, which can worsen the gastrointestinal symptoms commonly present in ME/CFS patients, affecting up to 40% of patients with IBS-like symptoms 13, 10

Evidence-Based Alternatives for Pain Management

• The guideline-supported options for pain management in ME/CFS include serotonin-norepinephrine reuptake inhibitors (SNRIs), such as duloxetine, which shows benefit for pain relief and improved functional status in fibromyalgia-like symptoms common in ME/CFS 9
• Pregabalin is also recommended, providing 30-50% pain relief and improving Patient Global Impression of Change scores, and is FDA-approved for fibromyalgia 9

Critical Clinical Pitfalls to Avoid

• The guideline recommends against prescribing hydrocodone based on patient reports of severe pain alone without attempting evidence-based alternatives first, and emphasizes the importance of documenting trials of CBT, SNRIs, or pregabalin before considering opioid therapy 13, 9
• The correct clinical pathway involves ruling out treatable causes of pain, initiating CBT and/or mindfulness-based therapy, trialing SNRI or pregabalin for pain, and adding complementary approaches as needed, with regular reassessment using a 0-10 numeric scale 9, 13

Additional Medications to Avoid

• The guideline recommends against the use of stimulants, such as methylphenidate and modafinil, in ME/CFS patients, despite fatigue understimulation being a core symptom, as harms outweigh benefits 9
• NSAIDs are also not recommended for chronic pain in ME/CFS, due to insufficient evidence for benefit in fibromyalgia-like pain, and corticosteroids, antivirals, antibiotics, and mifepristone are not demonstrated to be beneficial 10, 9

Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Primary Care and Specialist Referrals

• The VA/DoD Clinical Practice Guideline recommends that primary care physicians lead the management of ME/CFS, serving as the central coordinator for all aspects of care, and that ME/CFS requires an interdisciplinary team rather than referral to a single specialty 14
• Gastroenterologists should be consulted when gastrointestinal symptoms predominate, as up to 40% of ME/CFS patients have IBS-like symptoms 14
• Neurologists may be involved for cognitive impairment assessment and management of headaches, which are common in chronic multisymptom illness 14
• The VA/DoD Clinical Practice Guideline recommends against the use of long-term opioids, stimulants, corticosteroids, antivirals, or antibiotics, as these have no demonstrated benefit 15, 16

Evidence‑Based Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

First‑Line Non‑Pharmacological Interventions

• Cognitive‑behavioral therapy (CBT) is recommended as a primary intervention because it yields moderate to strong improvements in fatigue, psychological distress, cognitive symptoms, and overall mental‑health functioning in adults with ME/CFS. [17][18]
• Mindfulness‑based stress reduction or mindfulness‑based CBT should be offered; randomized trials show moderate effect sizes for enhanced quality of life compared with wait‑list controls. 18
• Emotion‑focused therapy may be considered for patients whose presentation includes prominent fibromyalgia‑like or irritable‑bowel‑syndrome‑like symptoms. [17][19]

Pharmacological Management – Interventions to Avoid

• Long‑term opioid therapy is strongly discouraged for chronic pain in ME/CFS because potential harms and burdens outweigh any theoretical benefit. [17][18]
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) should not be used for chronic pain related to ME/CFS. [17][19]
• Mifepristone is not recommended as it has demonstrated no therapeutic benefit in this population. 18

Pharmacological Management – Options with Limited Evidence

• Serotonin‑norepinephrine reuptake inhibitors (e.g., duloxetine) can be trialed for pain relief and functional improvement, particularly when fibromyalgia‑like symptoms predominate; evidence is limited but suggests benefit. [17][19]
• Pregabalin may be used for pain management, providing approximately 30 %–50 % pain reduction in fibromyalgia‑like presentations; evidence remains modest. [17][19]
• Mirtazapine, selective serotonin reuptake inhibitors, and amitriptyline lack sufficient evidence for routine use in ME/CFS. [17][19]

Complementary and Alternative Approaches

• Biofeedback, manual musculoskeletal therapies, relaxation therapy, guided imagery, and hypnosis have insufficient evidence to support firm recommendations for routine use in ME/CFS. [17][18]19